Thiazolidinediones × glycemic control

TrialJournal of internal medicine2009

Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.

M Roden et al.PubMed ↗Publisher ↗

  • Pioglitazonelooks good hereLower fasting FFAs, no range given.No ranges given.

What the trial testedas reported · 1,269 people · 2009

No range given

Reported lower fasting FFAs, no range given

−0.08

pioglitazone vs metformin, in added to sulfonylurea

As reported

difference −0.08, no interval

No range given

Reported lower fasting FFAs, no range given

−0.11

pioglitazone vs metformin, in added to metformin

As reported

difference −0.11, no interval

Who was studied, and how

1,269people with type 2 diabetes, in this paper

Among added to sulfonylurea, the trial randomly assignedassigned by chance

pioglitazone
metformin

Reported lower fasting FFAs, no range given−0.08

randomised

Among added to metformin, the trial randomly assignedassigned by chance

pioglitazone
metformin

Reported lower fasting FFAs, no range given−0.11

randomised

the abstract, start to end

treatment decreased fasting FFAs by 0.08 mmol L(-1) when added to sulfonylurea and by 0.11 mmol L(-1) when added to

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Fasting FFAspioglitazone vs metformin, in added to sulfonylurea
−0.08
Fasting FFAspioglitazone vs metformin, in added to metformin
−0.11
ThiazolidinedionesGlycemic control
1 / 4

6 papers cite it

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 19298459